BR112013025630A2 - pyridopyrazine derivatives and their use - Google Patents
pyridopyrazine derivatives and their useInfo
- Publication number
- BR112013025630A2 BR112013025630A2 BR112013025630A BR112013025630A BR112013025630A2 BR 112013025630 A2 BR112013025630 A2 BR 112013025630A2 BR 112013025630 A BR112013025630 A BR 112013025630A BR 112013025630 A BR112013025630 A BR 112013025630A BR 112013025630 A2 BR112013025630 A2 BR 112013025630A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyridopyrazine
- pyridopyrazine derivatives
- derivatives
- mammals
- enzymes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
Abstract
resumo patente de invenção:"derivados de piridopirazina e seu uso". a presente invenção fornece novos compostos de piridopirazina que são adequados para o tratamento ou prevenção de estados fisiológicos e/ou patofisiológicos mediados e/ou modulados por séries de reação de transdução de sinal e/ou enzimas em mamíferos e em particular em humanos.Patent Summary: "Pyridopyrazine derivatives and their use". The present invention provides novel pyridopyrazine compounds which are suitable for the treatment or prevention of physiological and / or pathophysiological conditions mediated and / or modulated by signal transduction reaction series and / or enzymes in mammals and in particular in humans.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472245P | 2011-04-06 | 2011-04-06 | |
| EP11161248A EP2508184A1 (en) | 2011-04-06 | 2011-04-06 | Pyridopyrazine derivatives and their use |
| PCT/EP2012/056142 WO2012136694A1 (en) | 2011-04-06 | 2012-04-04 | Pyridopyrazine derivatives and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013025630A2 true BR112013025630A2 (en) | 2016-12-27 |
Family
ID=44350566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013025630A BR112013025630A2 (en) | 2011-04-06 | 2012-04-04 | pyridopyrazine derivatives and their use |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8912189B2 (en) |
| EP (3) | EP2508184A1 (en) |
| JP (2) | JP5963844B2 (en) |
| KR (2) | KR20140025443A (en) |
| CN (2) | CN103826636A (en) |
| AR (2) | AR085844A1 (en) |
| AU (2) | AU2012238678B2 (en) |
| BR (1) | BR112013025630A2 (en) |
| CA (2) | CA2832321A1 (en) |
| ES (1) | ES2552515T3 (en) |
| IL (2) | IL228436A0 (en) |
| MX (2) | MX2013011490A (en) |
| NZ (1) | NZ615578A (en) |
| PL (1) | PL2694067T3 (en) |
| RU (2) | RU2013146618A (en) |
| SG (2) | SG193978A1 (en) |
| TW (2) | TWI564299B (en) |
| WO (2) | WO2012136691A1 (en) |
| ZA (2) | ZA201306862B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
| US20170168056A1 (en) * | 2015-11-13 | 2017-06-15 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating cancer cells |
| BR112018012914B1 (en) | 2015-12-22 | 2023-04-18 | SHY Therapeutics LLC | COMPOUND, USE OF A COMPOUND AND PHARMACEUTICAL COMPOSITION |
| WO2017180817A1 (en) * | 2016-04-15 | 2017-10-19 | Musc Foundation For Research Development | Treatment of septicemia and ards with erk inhibitors |
| KR20200041294A (en) | 2017-06-21 | 2020-04-21 | 샤이 테라퓨틱스 엘엘씨 | Compounds that interact with the Ras superfamily for the treatment of cancer, inflammatory diseases, neurodevelopmental diseases and fibrosis diseases |
| EP3641794A4 (en) * | 2017-06-23 | 2021-03-24 | The Trustees of Columbia University in the City of New York | Methods of preventing and treating diseases characterized by synaptic dysfunction and neurodegeneration including alzheimer's disease |
| US20210238605A1 (en) * | 2018-06-15 | 2021-08-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity |
| CN112830897B (en) * | 2019-11-22 | 2022-09-09 | 石家庄以岭药业股份有限公司 | Ureido-containing benzimidazole derivative and preparation method and application thereof |
| EP4271675A1 (en) * | 2020-12-31 | 2023-11-08 | Evrys Bio, LLC | Anti-tumor compositions and methods |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3809695A (en) | 1967-04-19 | 1974-05-07 | Degussa | 2,6-dichloro-3-nitro-pyridine |
| KR100369275B1 (en) | 1995-03-28 | 2003-05-09 | 스미또모 가가꾸 고오교오 가부시끼가이샤 | Preparation method of aminonitropyridines |
| UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
| JP4403482B2 (en) | 1997-12-22 | 2010-01-27 | バイエル コーポレイション | Intermediates for the synthesis of substituted heterocyclic ureas and methods for their preparation |
| CN101851173A (en) | 2001-09-14 | 2010-10-06 | 梅特希尔基因公司 | Inhibitors of histone deacetylase |
| WO2003068223A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
| JP4451136B2 (en) | 2002-04-08 | 2010-04-14 | メルク エンド カムパニー インコーポレーテッド | Akt activity inhibitor |
| AU2003226301A1 (en) | 2002-04-08 | 2003-10-20 | Merck And Co., Inc. | Method of treating cancer |
| US7223738B2 (en) | 2002-04-08 | 2007-05-29 | Merck & Co., Inc. | Inhibitors of Akt activity |
| US7718651B2 (en) | 2002-07-02 | 2010-05-18 | Southern Research Institute | Inhibitors of FtsZ and uses thereof |
| DE502004008322D1 (en) | 2003-05-23 | 2008-12-04 | Aterna Zentaris Gmbh | NEW PYRIDOPYRACINES AND THEIR USE AS MODULATORS OF KINASES |
| DE10323345A1 (en) * | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | New pyridopyrazines and their use as kinase inhibitors |
| WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
| AU2004297235A1 (en) | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
| GB0413953D0 (en) | 2004-06-22 | 2004-07-28 | Syngenta Participations Ag | Chemical compounds |
| EP1790342A1 (en) * | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazine derivatives and their use as signal transduction modulators |
| AU2006313701B2 (en) | 2005-11-11 | 2012-05-31 | Aeterna Zentaris Gmbh | Novel pyridopyrazines and their use as modulators of kinases |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| EP1785423A1 (en) * | 2005-11-11 | 2007-05-16 | Zentaris GmbH | Pyridopyrazine derivatives and their use as kinase modulators |
| US7733554B2 (en) * | 2006-03-08 | 2010-06-08 | E Ink Corporation | Electro-optic displays, and materials and methods for production thereof |
| KR101097177B1 (en) | 2006-07-06 | 2011-12-22 | 한국화학연구원 | 2-Alkylenyloxy-3-ethynylpyrido[2,3-b]pyrazine derivatives |
| GB0614471D0 (en) | 2006-07-20 | 2006-08-30 | Syngenta Ltd | Herbicidal Compounds |
| US20100093738A1 (en) | 2006-10-06 | 2010-04-15 | Basf Se | Fungicidal Compounds and Fungicidal Compositions |
| EP1990342A1 (en) * | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof |
| WO2009073513A1 (en) * | 2007-11-30 | 2009-06-11 | Schering Corporation | Braf biomarkers |
| BRPI0821227A2 (en) | 2007-12-19 | 2015-06-16 | Cancer Rec Tech Ltd | Compound, pharmaceutical composition, method for preparing same, use of a compound, method for treating a disease or disorder, for inhibiting raf function and for inhibiting cell proliferation, inhibiting cell cycle progression, promoting apoptosis, or a combination of one or more more of them |
-
2011
- 2011-04-06 EP EP11161248A patent/EP2508184A1/en not_active Withdrawn
-
2012
- 2012-04-03 TW TW101111889A patent/TWI564299B/en not_active IP Right Cessation
- 2012-04-03 TW TW101111888A patent/TW201302742A/en unknown
- 2012-04-04 RU RU2013146618/04A patent/RU2013146618A/en not_active Application Discontinuation
- 2012-04-04 BR BR112013025630A patent/BR112013025630A2/en not_active IP Right Cessation
- 2012-04-04 KR KR1020137029386A patent/KR20140025443A/en not_active Application Discontinuation
- 2012-04-04 WO PCT/EP2012/056138 patent/WO2012136691A1/en active Application Filing
- 2012-04-04 SG SG2013072624A patent/SG193978A1/en unknown
- 2012-04-04 JP JP2014503125A patent/JP5963844B2/en not_active Expired - Fee Related
- 2012-04-04 JP JP2014503127A patent/JP2014510125A/en active Pending
- 2012-04-04 US US13/439,107 patent/US8912189B2/en not_active Expired - Fee Related
- 2012-04-04 US US13/439,150 patent/US8791118B2/en not_active Expired - Fee Related
- 2012-04-04 EP EP12713706.5A patent/EP2694068A1/en not_active Withdrawn
- 2012-04-04 CA CA2832321A patent/CA2832321A1/en not_active Abandoned
- 2012-04-04 NZ NZ615578A patent/NZ615578A/en not_active IP Right Cessation
- 2012-04-04 AU AU2012238678A patent/AU2012238678B2/en not_active Ceased
- 2012-04-04 CN CN201280019613.9A patent/CN103826636A/en active Pending
- 2012-04-04 MX MX2013011490A patent/MX2013011490A/en unknown
- 2012-04-04 KR KR1020137029385A patent/KR20140025442A/en not_active Application Discontinuation
- 2012-04-04 ES ES12713705.7T patent/ES2552515T3/en active Active
- 2012-04-04 CA CA2832337A patent/CA2832337A1/en not_active Abandoned
- 2012-04-04 MX MX2013011444A patent/MX2013011444A/en unknown
- 2012-04-04 WO PCT/EP2012/056142 patent/WO2012136694A1/en active Application Filing
- 2012-04-04 AR ARP120101163A patent/AR085844A1/en unknown
- 2012-04-04 AR ARP120101162A patent/AR085843A1/en unknown
- 2012-04-04 SG SG2013074430A patent/SG194097A1/en unknown
- 2012-04-04 EP EP12713705.7A patent/EP2694067B1/en active Active
- 2012-04-04 PL PL12713705T patent/PL2694067T3/en unknown
- 2012-04-04 RU RU2013146619/15A patent/RU2013146619A/en not_active Application Discontinuation
- 2012-04-04 CN CN201280022158.8A patent/CN103501788A/en active Pending
- 2012-04-04 AU AU2012238681A patent/AU2012238681A1/en not_active Abandoned
-
2013
- 2013-09-12 ZA ZA2013/06862A patent/ZA201306862B/en unknown
- 2013-09-12 ZA ZA2013/06864A patent/ZA201306864B/en unknown
- 2013-09-15 IL IL228436A patent/IL228436A0/en unknown
- 2013-09-15 IL IL228433A patent/IL228433A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013025630A2 (en) | pyridopyrazine derivatives and their use | |
| BRPI0618451A2 (en) | pyridopyrazine derivatives, their use, pharmaceutical composition and kit | |
| EA201390609A1 (en) | HIDANTOIN DERIVATIVES USEFUL AS KV3-CHANNEL INHIBITORS | |
| BR112014004504A2 (en) | "compound as c-kit kinase inhibitor, its use, pharmaceutical composition, and medicament for the treatment of a kinase mediated disease" | |
| WO2014062720A3 (en) | Methods of treating cancer | |
| BR112013020500A8 (en) | isolated, recombinant or purified antibody | |
| BR112015014372A8 (en) | autotaxin inhibitors, their uses, and pharmaceutical composition and combination ". | |
| BR112015003592A2 (en) | 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections | |
| MA33803B1 (en) | BENZODIAZEPINE BROMODOMAINE INHIBITOR | |
| BR112014004560A2 (en) | compounds and compositions as c-kit kinase inhibitors | |
| BR112013002484A2 (en) | compound, pharmaceutical composition, methods for treating multiple sclerosis and rheumatoid arthritis, and use of a compound. | |
| CR20130487A (en) | 1,3-oxazines as inhibitors of BACE1 and / or BACE2 | |
| CR20130588A (en) | HALOGENOALQUIL-1,3-OXAZINAS AS INHIBITORS OF THE BACE1 AND / OR BACE 2 | |
| BR112012027034A2 (en) | arginase inhibitors and their therapeutic applications | |
| BR112013010310A2 (en) | lactam acetylcholine carboxylase inhibitors n1 / n2 | |
| EA201001847A1 (en) | COMPOUNDS AND COMPOSITIONS APPLICABLE FOR THE TREATMENT OF MALARIA | |
| BR112014009415A2 (en) | arginase inhibitors and their therapeutic applications | |
| BR112013021236A2 (en) | compound, composition, and method of treating a disorder, condition or disease | |
| IN2014CN04907A (en) | ||
| BRPI0906478B8 (en) | anti-nr10 antibody, its use and pharmaceutical composition comprising it | |
| EA201200559A1 (en) | METHODS OF APPOINTMENT PYRPHENIDONE THERAPY | |
| BR112014004465A2 (en) | compounds and compositions as pdgfr kinase inhibitors | |
| BR112014009866A2 (en) | antibody formulations and methods | |
| WO2011077043A3 (en) | Phenol derivatives and pharmaceutical or cosmetic use thereof | |
| IN2012DN00971A (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |